Insulin Degludec vs Peglispro
Insulin degludec (Tresiba) and insulin peglispro (LY2605541) represent two distinct approaches to ultra-long-acting insulin engineering. Degludec uses multi-hexamer formation for ultra-long absorption; peglispro uses polyethylene glycol (PEG)ylation for hepatoselectivity and extended duration. Understanding their pharmacological differences is essential for rational ultra-long-acting insulin selection.
Molecular Engineering
Section titled “Molecular Engineering”Insulin Degludec
Section titled “Insulin Degludec”Degludec achieves ultra-long action through self-association:
- Sequence: Human insulin with ThrB30 deletion and γ-glutamic acid spacer at LysB29
- Acylation: C-16 fatty hexadecanedioic acid at LysB29 via γ-glutamic acid linker
- Mechanism: Fatty acid promotes multi-hexamer formation in subcutaneous tissue
- Molecular weight: ~6,100 Da (monomer)
- Half-life: ~25 hours (once-daily dosing)
After subcutaneous injection, degludec monomers self-associate into di-hexamers and multi-hexamers, forming a soluble depot. Multi-hexamers dissociate slowly into di-hexamers → monomers → absorb into circulation, where monomers bind albumin via the fatty acid moiety.
Insulin Peglispro
Section titled “Insulin Peglispro”Peglispro achieves ultra-long action through PEGylation:
- Sequence: Human insulin with LysB28 → Pro mutation (lispro backbone)
- Modification: 20 kDa linear PEG moiety covalently attached at LysB29
- Mechanism: PEG reduces renal clearance and provides steric shielding
- Molecular weight: ~26,300 Da (PEGylated)
- Half-life: ~46 hours (once-daily dosing)
The large PEG moiety dramatically increases hydrodynamic radius, reducing glomerular filtration. PEG also provides steric shielding against proteolytic degradation and reduces insulin receptor binding kinetics — producing hepatoselectivity.
Pharmacokinetic Comparison
Section titled “Pharmacokinetic Comparison”| Parameter | Degludec | Peglispro |
|---|---|---|
| Half-life | ~25 hours | ~46 hours |
| Onset | 30–90 min | 2–4 hours |
| Peak | ~9 hours (flat) | ~16–20 hours |
| Duration | >42 hours | >48 hours |
| Steady-state | 3–4 days | 5–6 days |
| Variability (CV) | <20% (lowest) | ~20–30% |
| Once-daily dosing | Yes | Yes |
Degludec achieves the lowest pharmacokinetic variability of any basal insulin (<20% CV), a property attributed to its multi-hexamer depot. Peglispro’s longer half-life provides more sustained action but with greater variability.
Hepatoselectivity: A Key Distinction
Section titled “Hepatoselectivity: A Key Distinction”Degludec: Non-Selective Distribution
Section titled “Degludec: Non-Selective Distribution”Degludec distributes to insulin-responsive tissues (muscle, fat, liver) through albumin-bound circulation:
- Muscle: Primary site of glucose disposal (~70% of insulin-mediated uptake)
- Adipose tissue: Lipogenesis regulation
- Liver: Gluconeogenesis suppression, glycogen synthesis
- Distribution: Conventional (no tissue selectivity)
Peglispro: Hepatoselective Action
Section titled “Peglispro: Hepatoselective Action”Peglispro’s 20 kDa PEG moiety creates hepatoselectivity through:
- Reduced muscle penetration: The large PEG sterically hinders transport across capillary endothelium to muscle tissue.
- Preserved hepatic access: The liver’s fenestrated sinusoidal endothelium allows larger molecules to reach hepatocytes.
- Differential receptor kinetics: PEGylation slows insulin receptor binding, favoring hepatic signaling over peripheral signaling.
Consequences of hepatoselectivity:
- Reduced peripheral glucose uptake (muscle) → lower hypoglycemia risk
- Enhanced hepatic glucose output suppression → improved fasting glucose
- Reduced lipogenesis in peripheral tissues → favorable lipid profile
- Increased hepatic de novo lipogenesis → potential concern
Clinical Evidence
Section titled “Clinical Evidence”Degludec: DEVOTE, BEGIN, SWITCH
Section titled “Degludec: DEVOTE, BEGIN, SWITCH”DEVOTE (CV safety, N=7,637):
- Degludec vs glargine U100 in high CV risk T2D
- Primary endpoint: Non-inferior CV safety (HR 0.91, p<0.001 for non-inferiority)
- Severe hypoglycemia: 40% reduction with degludec (HR 0.60, p<0.001)
BEGIN/ SWITCH trials:
- Similar HbA1c reduction with degludec and glargine
- Significantly lower nocturnal and overall hypoglycemia
- Flat, stable glucose-lowering profile
Peglispro: Phase II/III
Section titled “Peglispro: Phase II/III”Phase II (T2D):
- Peglispro showed similar HbA1c reduction vs insulin glargine
- Fasting glucose: Peglispro superior (−40 mg/dL vs −30 mg/dL)
- Triglycerides: Peglispro increased triglycerides (+25%) — a notable disadvantage
- Hepatic fat: Peglispro increased hepatic de novo lipogenesis
Development status: Eli Lilly discontinued peglispro development in 2015 due to:
- Hepatic safety concerns (elevated transaminases, hepatic fat accumulation)
- Hypertriglyceridemia
- Competitive landscape (degludec’s favorable profile)
Safety Comparison
Section titled “Safety Comparison”| Effect | Degludec | Peglispro |
|---|---|---|
| Severe hypoglycemia | Lowest (40% reduction vs glargine) | Low |
| Nocturnal hypoglycemia | Lowest | Low |
| Weight gain | Neutral | Neutral |
| Triglycerides | Neutral | Increased (+25%) |
| Hepatic fat | Neutral | Increased |
| Transaminases | Neutral | Elevated |
| Injection site reactions | Common (lipodystrophy) | Common |
| CV safety | Non-inferior (DEVOTE) | Unknown |
Peglispro’s hepatic effects — increased triglycerides, hepatic fat accumulation, and elevated transaminases — were the primary reason for its discontinuation. These effects relate directly to its hepatoselectivity and enhanced hepatic de novo lipogenesis.
Dosing and Administration
Section titled “Dosing and Administration”| Parameter | Degludec | Peglispro |
|---|---|---|
| Dose | Individualized | Individualized |
| Frequency | Once daily | Once daily |
| Time of day | Any (flexible) | Any (flexible) |
| Titration | Every 3–4 days | Every 3–4 days |
| Pen system | FlexTouch (multi-dose) | Discontinued |
| Needle gauge | 32G | N/A |
Degludec’s flexible dosing (any time of day, with or without meals) is a significant practical advantage over other basal insulins. Peglispro’s development was discontinued before commercial availability.
Summary
Section titled “Summary”Insulin degludec and insulin peglispro represent two distinct approaches to ultra-long-acting insulin. Degludec’s multi-hexamer formation produces the lowest pharmacokinetic variability of any basal insulin, with proven cardiovascular safety and 40% reduction in severe hypoglycemia vs glargine. Peglispro’s PEGylation achieved ultra-long duration and hepatoselectivity, but at the cost of hepatic fat accumulation, hypertriglyceridemia, and elevated transaminases — leading to development discontinuation in 2015. Degludec remains the preferred ultra-long-acting insulin, offering the optimal combination of pharmacokinetic stability, hypoglycemia reduction, and safety profile. Peglispro’s concept of hepatoselective insulin delivery remains pharmacologically interesting but clinically unvalidated.